Roche Launches uPath PD-L1 (SP263) Automated Digital Pathology Algorithm to Speed Up NSCLC Diagnosis

Roche Launches uPath PD-L1 (SP263) Automated Digital Pathology Algorithm to Speed Up NSCLC Diagnosis

Shots:

  • uPath PD-L1 (SP263) image analysis utilizes automated pre-computing and one-click scoring to enable quicker and accurate detection and measurement of tumor cell staining positivity
  • All algorithms in the suite for uPath software will provide image analysis of VENTANA DP 200 scanned slide images stained with a Roche tissue assay, allowing pathologists to quickly determine whether tumors are PD-L1 biomarker positive, highlighting positively & negatively stained tumor cells with a clear visual overlay for easy reference
  • This launch of uPath PD-L1 (SP263) image analysis for NSCLC follows the release of the Roche’s uPath enterprise software in Jan’2019. When used with the CE-marked VENTANA PD-L1 (SP263) Assay, uPath is indicated as an aid to identif patients for treatment with therapies with the ≥ 50% PD-L1 TC positivity cutoff in accordance with the approved therapeutic product labeling

Click here to read full press release/ article | Ref: Roche | Image: Roche